Novartis Settles Patent Litigation Over Gleevec
Novartis settles its litigation with the US subsidiary of Sun Pharma regarding Gleevec.
Novartis Pharmaceuticals has settled its litigation with the US subsidiary of Sun Pharmaceutical Industries, regarding patents covering the use of certain polymorphic forms of Gleevec (imatinib mesylate), which expire in 2019 (including pediatric exclusivity). The basic compound patent for Gleevec expires in the US on July 4, 2015.
As a result of the settlement, Novartis will permit Sun Pharma's subsidiary to market a generic version of Gleevec in the US on February 1, 2016. The terms of the settlement agreement are otherwise confidential. Sun Pharma's subsidiary has received tentative approval from FDA for its generic version of imatinib mesylate.
Source: Novartis Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
